Harvard Bioscience Inc. (HBIO) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HBIO scores 47 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:

• Fundamental Cash Engine: 8 / 20. Per the RQD rating, return on invested capital is -35% and FCF yield is 13.66%. The weak ROIC is the dominant drag here; the FCF yield is the single offsetting positive, but it sits alongside negative operating and net margins in the market data, so investors should not read the yield in isolation.
• Whale 13F Flow: 15 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar in the score, though the supporting holder detail is not present in the source data (see Analyst View).
• Insider Conviction: 9 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow, which the rating characterizes as weak conviction.
• Macro Regime Fit: 9 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move broadly in line with the market, offering no defensive cushion in a downturn.
• Forensic Balance Sheet: 6 / 20. Per the RQD rating, Altman Z is 0.2, Piotroski F is 5 out of 9, and Debt/Equity is 2.61. The Altman Z reading is in a range the rating treats as distress-adjacent, and leverage is elevated.

For a prospective investor, the practical implication is that the score points to an asymmetric setup: upside would need to come from a turnaround in operating economics, while the balance sheet and profitability pillars leave limited margin for error. The stock's 52-week range of $4 to $9 and recent price of 8.8 sit near the top of that range, so the market has already repriced some optimism. Valuation tradeoffs cannot be assessed fully because P/E, forward P/E, EV/EBITDA, and EPS are not available in the source data. This brief is educational and does not constitute personalized financial advice.

Harvard Bioscience Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Per the profile, the company's market capitalization is shown as $0.0B in the profile field, which conflicts with the $40.1M figure in the market data. Customer segments, product lines, and revenue mix are not available in source data. Per the SEC financials, reported revenue was $86.5M in FY 2025, down from $94.1M in FY 2024 and $112.2M in FY 2023.

Per the market data, gross margin is 57.7%, operating margin is -56.1%, and net margin is -60%, with ROIC at -35%. Revenue has declined across each reported period, and operating income moved from positive in FY 2023 to -$48.6M in FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5 out of 9. Per the RQD rating, Debt/Equity is 2.61, and reported debt rose from $0.0M in FY 2024 to $35.9M in FY 2025 against cash of $8.6M.

Per the recent news feed, the company announced the creation of a Scientific Advisory Board, which appears across multiple wire items. A third-quarter 2026 earnings conference call is scheduled for November 10, 2026 at 8:00 AM ET, making it the nearest concrete catalyst. One item references a holder reporting a 5.20 percent stake, though the holder identity and filing details are not available in source data. All news items carry a YELLOW light designation and a MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

• What are the drivers of the FY 2025 revenue decline and the swing to a $-48.6M operating loss, and are they expected to persist?
• What is the composition and maturity of the $35.9M debt, and how does it relate to the jump from $0.0M in FY 2024?
• Why is the FY 2025 FCF positive at $5.5M when net income is $-56.7M, and is that cash generation sustainable?
• What explains the discrepancy between the $0.0B market cap in the profile and the $40.1M in market data?
• Who is the holder reporting a 5.20 percent stake, and what are the terms and timing of the reported position?